Its active ingredient, Tirzepatide , is a dual GIP and GLP-1 receptor agonist
In Canada, the non-formulary claims for GLP-1 RAs increased by more than fourfold from 14,088 claimants in 2016 to 60,120 claimants in 2021 [6]
In contrast to the enhancement of spontaneous excitatory postsynaptic transmission (Mietlicki-Baase et al., 2013), using retrograde labeling of VTA to nucleus accumbens (NAc) medial shell projecting neurons, in vitro patch-clamp recordings showed that exendin-4 selectively inhibits the miniature excitatory postsynaptic currents (mEPSCs) within the dopaminergic VTA-to-NAc projection neurons (Wang et al., 2015
In particular, in the case of off-label drugs, it is difficult to officially manage medical staff in the event of side effects, and there are limitations in insurance application, damage relief, and holding the manufacturer responsible
At AlphaMD, a leading m
The effect is real but far smaller than what a prescription GLP-1 drug produces